Yahoo
OTC Markets OTCPK - Delayed Quote USD

BioGaia AB (publ) (BIOGY)

12.45 0.00 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for BIOGY
  • Previous Close 12.45
  • Open 11.73
  • Bid 9.75 x 30000
  • Ask 12.42 x 30000
  • Day's Range 11.73 - 11.73
  • 52 Week Range 9.64 - 12.45
  • Volume 1
  • Avg. Volume 14
  • Market Cap (intraday) 1.259B
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) 30.37
  • EPS (TTM) 0.41
  • Earnings Date --
  • Forward Dividend & Yield 0.42 (3.40%)
  • Ex-Dividend Date May 11, 2026
  • 1y Target Est --

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.

www.biogaiagroup.com

251

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

BIOGY
17.81%
OMX Stockholm 30 Index (^OMX)
13.47%

1-Year Return

BIOGY
24.86%
OMX Stockholm 30 Index (^OMX)
17.56%

3-Year Return

BIOGY
66.02%
OMX Stockholm 30 Index (^OMX)
59.03%

5-Year Return

BIOGY
35.58%
OMX Stockholm 30 Index (^OMX)
42.80%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 400.4M
Earnings 110.21M
Profit Margin 27.52%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
100M
200M
300M
400M
22.0%
24.0%
26.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.67%

  • Return on Assets (ttm)

    19.86%

  • Return on Equity (ttm)

    32.10%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    0.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    168.37M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: